Inflammatory Bowel Disease Ibd clinical trials

Explore recruiting inflammatory bowel disease ibd clinical trials.

Recruiting inflammatory bowel disease ibd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Inflammatory Bowel Disease Ibd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Investigating the safety, feasibility, and optimal dose of fluorescently labeled Adalimumab-680LT for visualizing drug targeting in Inflammatory Bowel Diseases.

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Investigating the safety, feasibility, and optimal dose of risankizumab-800CW for visualizing drug targeting in Inflammatory Bowel Disease

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Analgesic effect of intravenous lidocaïne and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b Extension Study to Evaluate the Long-Term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease

Spain, Ireland, Portugal, Poland, Belgium, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease Long-term Safety With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease.

Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Inflammatory Bowel Disease Ibd trials by city

Inflammatory Bowel Disease Ibd in Toronto Inflammatory Bowel Disease Ibd in Vancouver Inflammatory Bowel Disease Ibd in Montreal Inflammatory Bowel Disease Ibd in Calgary Inflammatory Bowel Disease Ibd in Edmonton Inflammatory Bowel Disease Ibd in Ottawa Inflammatory Bowel Disease Ibd in Winnipeg Inflammatory Bowel Disease Ibd in Quebec City Inflammatory Bowel Disease Ibd in Hamilton Inflammatory Bowel Disease Ibd in Kitchener Inflammatory Bowel Disease Ibd in London Inflammatory Bowel Disease Ibd in Halifax Inflammatory Bowel Disease Ibd in New York Inflammatory Bowel Disease Ibd in Los Angeles Inflammatory Bowel Disease Ibd in Chicago Inflammatory Bowel Disease Ibd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease